Surgery for pancreatic cancer: current controversies and challenges

被引:36
作者
Karunakaran, Monish [1 ,2 ]
Barreto, Savio George [3 ,4 ]
机构
[1] Medanta Medicity, Dept Gastrointestinal Surg Gastrointestinal Oncol, Medanta Inst Digest & Hepatobiliary Sci, Gurugram 122001, India
[2] Medanta Medicity, Dept Liver Transplantat & Regenerat Med, Gurugram 122001, India
[3] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[4] Flinders Med Ctr, Div Surg & Perioperat Med, Adelaide, SA, Australia
关键词
extended pancreatectomy; lymphadenectomy; minimally invasive pancreatic surgery; neoadjuvant therapy; pancreatic cancer; vascular resections; CELIAC AXIS RESECTION; MESENTERIC VEIN RESECTION; LYMPH-NODE RATIO; INTERNATIONAL STUDY-GROUP; LAPAROSCOPIC DISTAL PANCREATECTOMY; RANDOMIZED CLINICAL-TRIAL; LEFT GASTRIC ARTERY; LONG-TERM SURVIVAL; EN-BLOC RESECTION; PORTAL-VEIN;
D O I
10.2217/fon-2021-0533
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Two main areas of focus in pancreatic cancer research are the high rates of post-surgery complications and poor survival despite completely removing the tumor. Complete, margin-negative resection (where some healthy tissue is removed to ensure the whole tumor is cut out) is the only way to ensure long-term survival. However, such extensive resections, especially when they involve nearby blood vessels and/or organs, should only be undertaken if the imaging done pre-surgery indicates the possibility that a complete, margin-negative resection can be achieved. It should be noted that the removal of lymph nodes, in addition to the ones normally removed during a pancreatic resection, does not confer a survival benefit. Distal pancreatectomy (performed for tumors involving the body or tail of the pancreas) is safe and feasible using minimal access methods; however, the safety of minimally-invasive pancreatoduodenectomy (performed for tumors of the head of the pancreas) remains to be proven. The oncological benefit of minimally-invasive distal pancreatectomy over open surgery has not been established. Two areas that remain the focus of improvement in pancreatic cancer include high post-operative morbidity and inability to uniformly translate surgical success into long-term survival. This narrative review addresses specific aspects of pancreatic cancer surgery, including neoadjuvant therapy, vascular resections, extended pancreatectomy, extent of lymphadenectomy and current status of minimally invasive surgery. R0 resection confers longer disease-free survival and overall survival. Vascular and adjacent organ resections should be undertaken after neoadjuvant therapy, only if R0 resection can be ensured based on high-quality preoperative imaging, and that too, with acceptable post-operative morbidity. Extended lymphadenectomy does not offer any advantage over standard lymphadenectomy. Although minimally invasive distal pancreatectomies offers some short-term benefits over open distal pancreatectomy, safety remains a concern with minimally invasive pancreatoduodenectomy. Strict adherence to principles and judicious utilization of surgery within a multimodality framework is the way forward.
引用
收藏
页码:5135 / 5162
页数:28
相关论文
共 50 条
  • [21] Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies
    Stopa, Kinga B.
    Kusiak, Agnieszka A.
    Szopa, Mateusz D.
    Ferdek, Pawel E.
    Jakubowska, Monika A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [22] Borderline resectable pancreatic cancer: Certainties and controversies
    Nappo, Gennaro
    Donisi, Greta
    Zerbi, Alessandro
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 13 (06): : 516 - 528
  • [23] Current opinion on lymphadenectomy in pancreatic cancer surgery
    Pavlidis, Theodoros E.
    Pavlidis, Efstathios T.
    Sakantamis, Athanasios K.
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2011, 10 (01) : 21 - 25
  • [24] Current opinion on lymphadenectomy in pancreatic cancer surgery
    Theodoros E Pavlidis
    Efstathios T Pavlidis
    Athanasios K Sakantamis
    Hepatobiliary&PancreaticDiseasesInternational, 2011, 10 (01) : 21 - 25
  • [25] Borderline resectable pancreatic cancer
    Hackert, Thilo
    Ulrich, Alexis
    Buechler, Markus W.
    CANCER LETTERS, 2016, 375 (02) : 231 - 237
  • [26] Current Status of Adjuvant Therapy for Pancreatic Cancer
    Katz, Matthew H. G.
    Fleming, Jason B.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    ONCOLOGIST, 2010, 15 (11) : 1205 - 1213
  • [27] Pancreatic cancer: open or minimally invasive surgery?
    Zhang, Yu-Hua
    Zhang, Cheng-Wu
    Hu, Zhi-Ming
    Hong, De-Fei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (32) : 7301 - 7310
  • [28] Current controversies and advances in the management of pancreatic adenocarcinoma
    Zeeshan, Muhammad Shehroz
    Ramzan, Zeeshan
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (06) : 427 - 494
  • [29] Challenges and controversies in adrenal surgery: A practical approach
    Beninato, Toni
    Duh, Quan-Yang
    Kiernan, Colleen M.
    Long, Kristin L.
    Miller, Barbra S.
    Patel, Snehal
    Randle, Reese W.
    Wachtel, Heather
    Zanocco, Kyle A.
    Zern, Nicole K.
    Drake, Frederick Thurston
    CURRENT PROBLEMS IN SURGERY, 2023, 60 (09)
  • [30] Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
    Manrai, Manish
    Tilak, T. V. S. V. G. K.
    Dawra, Saurabh
    Srivastava, Sharad
    Singh, Anupam
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (39) : 6572 - 6589